EcoDrugPlus

Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1e

Ensembl ID : ENSORLG00000017409
Gene Symbol: LOC101173258
3 Cross references
180 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSORLG00000008646
Gene Symbol: LOC101161218
3 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit

Ensembl ID : ENSORLG00000006028
Gene Symbol: LOC101163260
4 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit

Ensembl ID : ENSORLG00000022002
Gene Symbol: LOC101167457
4 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit

Ensembl ID : ENSORLG00000006043
Gene Symbol: LOC101163670
4 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit

Ensembl ID : ENSORLG00000022053
Gene Symbol: LOC101173155
4 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1

Ensembl ID : ENSORLG00000015164
Gene Symbol: LOC101156213
3 Cross references
226 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-4

Ensembl ID : ENSORLG00000000721
Gene Symbol: LOC101171407
3 Cross references
228 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSORLG00000001080
Gene Symbol: XDH
4 Cross references
208 Possible Orthologues:

Ensembl ID : ENSORLG00000021795
Gene Symbol: -
Cross references: -
221 Possible Orthologues:

Ensembl ID : ENSORLG00000028309
Gene Symbol: -
Cross references: -
428 Possible Orthologues:

Ensembl ID : ENSORLG00000022851
Gene Symbol: -
Cross references: -
169 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).